Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Up - Time to Buy?

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $12.72, but opened at $13.84. Bicara Therapeutics shares last traded at $12.96, with a volume of 26,795 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on BCAX shares. RODMAN&RENSHAW raised Bicara Therapeutics to a "strong-buy" rating in a research note on Tuesday, November 5th. HC Wainwright raised their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a "buy" rating in a research report on Monday, January 27th. Wedbush began coverage on shares of Bicara Therapeutics in a research report on Thursday. They issued an "outperform" rating and a $31.00 target price for the company. Finally, Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They set a "buy" rating and a $48.00 price target on the stock. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $41.20.

Bicara Therapeutics Price Performance

The business's 50 day moving average is $15.66.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). As a group, equities analysts forecast that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Spire Wealth Management bought a new position in shares of Bicara Therapeutics during the fourth quarter valued at $31,000. SG Americas Securities LLC acquired a new stake in Bicara Therapeutics during the 4th quarter worth $147,000. Cinctive Capital Management LP acquired a new position in Bicara Therapeutics during the third quarter valued at approximately $229,000. Barclays PLC acquired a new position in Bicara Therapeutics in the third quarter valued at about $255,000. Finally, Jane Street Group LLC acquired a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $309,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.